Crossmark

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by <scp>CDK</scp> 4/6 inhibitor palbociclib

Crossref DOI link: https://doi.org/10.15252/embj.201798359

Published Online: 2018-04-18

Published Print: 2018-05-15

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Miettinen, Teemu P

Peltier, Julien

Härtlova, Anetta

Gierliński, Marek

Jansen, Valerie M

Trost, Matthias https://orcid.org/0000-0002-5732-700X
Björklund, Mikael
Funding

Funding for this research was provided by:

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline

Janssen Pharmaceuticals

Merck KGaA

Pfizer

Wellcome Trust (097945/Z/11/Z, 110275/Z/15/Z)

Medical Research Council (MC_UU_12016/5)

Biotechnology and Biological Sciences Research Council (BB/L008874/1)

Conquer Cancer Foundation (8364)

Susan G. Komen (15329319)

School of Medicine, Vanderbilt University (2K12CA090625‐17)
License Information

Version of Record valid from 2018-04-18
More Information

Publication History

Received: 2017-10-09

Accepted: 2018-03-09

Published: 2018-04-18